Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
  • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
  • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
  • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
  • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
  • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
  • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
  • A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
  • A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
  • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
  • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
  • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
  • A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
  • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
  • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
  • A23G3/50—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
  • A23G3/54—Composite products, e.g. layered, coated, filled

Definitions

• This invention relates to functional confectionery compositions in the form of compacts that provide energy and stimulation.
• Glucose is the basic energy provider to the body. It is directly absorbed from the gastrointestinal (GI) tract and transported in the circulation to provide immediate energy in metabolic processes or stored as other forms of energy. In fatigue states the requirement for glucose increases and if this is not readily available, physical functions may deteriorate rapidly with diminishing mental acuity and wakefulness. Direct intake of sugar and particularly glucose helps combat fatigue. Furthermore, compounds such as the xanthines, particularly caffeine may promote wakefulness directly through central nervous system (CNS) stimulation, and indirectly through mobilisation of insulin which increases cellular uptake of glucose. Energy boosting products essentially containing glucose and sugars are widely used as drinks, snacks and sweets to prevent fatigue. Alternatively, products containing a therapeutic dose of a stimulant such as caffeine in a tablet are also available.
• GI gastrointestinal
• the object of this invention is at least two fold. Firstly, to improve and extend the oral bioavailability of caffeine and energy producing sugar combinations with improved delivery to enable maximum oral and mucosal absorption in the form of compacts /sweets so that a unit dose of less than 30 mg or lower may be an effective amount as a stimulant. Secondly, to provide stimulation compositions in the form of sweets comprising caffeine or a stimulant within an effective and safe dose range in sealed unit packs, thereby avoiding or minimising the risk of caffeine overdose through over indulgence.
• the sweets are in the form of compacts in a visually attractive and distinctive bicoloured, bilayer presentation which further enables active compounds, incompatible or different ingredients and flavours to be contained in separate layers.
• EP 0 716,853 describes caffeine tablets with 100 mg to 700 mg caffeine in each in a slow release solid matrix form for extended release in the GI tract.
• DE 3,821,374 relates to coffee sweets with skimmed milk, whole milk and and/ or creamer of vegetable origin, and in addition sugar/ sweetener. In accordance with the desired taste, greater or lesser portions of coffee are selected for the base mass.
• WO 00/13522 describes a comestible delivery system which is a chewy nougat composition prepared by positively hydrating a mixture of components including a hydro bonding compound , a saccharide based material and a bio-affecting substance having poor organoleptic characteristics to form a mass without need for cooking to drive off moisture.
• US 4,452,821 describes confectionery compositions comprising caffeine in a solid wax mixture incorporated into a confectionery base.
• US 6,024,988 discloses caffeine in taste masked form by virtue of particle size characteristics whilst US 6,627,234 is concerned with compositions containing caffeine added to the coating material.
• Confectionery products e.g. mints
• mints are in a separate functional group clearly for mouth freshening and do not claim the benefits of novel energy providing sugar compositions particularly with trehalose.
• bilayered presentations of sweets in the form of compacts are unique and have not been described before.
• the typical caffeine content of some known proprietary products is listed below. For comparison the caffeine content of daily beverages is also shown.
• Pro-Plus ® Caffeine 50 mg. Recommended dose 1 to 2 tabs. Not to exceed 2 tablets in 1 hour and 12 tablets in 24 hours.
• Pep ® Caffeine alkaloid BP 30 mg. 2 tablets up to three times a day.
• Stimulation Drinks 250 ml can
• the invention is in the area of 'functional confectionery' and 'stimulation sweets'. It stradles nutriceutical and confectionery compositions and combines the functional benefits of a nutriceutical with the pleasurable and flavoursome properties of a confectionery.
• the invention provides a controlled supply of energy sugars and at least one stimulant compound for maintaining a wakeful and alert state and improving cognitive ability.
• the invention in one aspect relates to a functional confectionery composition in a pack containing stimulation sweets in the form of compacts comprising: i) sugars selected from the group consisting of mono, di and poly saccharides, ii) a stimulant.
• the invention further describes a functional confectionery composition which may be stimulation sweets in the form of compacts in a pack comprising; i) sugars selected from the group consisting of mono, di and poly saccharides, ii) 0.1 to 10 mg caffeine in each sweet, iii) an effective amount of caffeine.
• the invention further describes a functional confectionery composition which may be stimulation sweets in the form of compacts in a pack comprising;
• trehalose ii) 0.1 to 10 mg caffeine in each sweet.
• Preferred embodiments of the invention comprise a functional confectionery composition in a pack containing 5 to 100 compacts.
• the invention describes a method to extend the beneficial effects from at least one energy provider in association with at least one stimulant agent. Furthermore, the invention minimises acute overdose of stimulant by providing a functional composition in a sealed unit pack comprising a total amount of a stimulant equivalent to between 1 to 20 doses.
• each dose in the pack comprises an effective dose which may be 10 mg, preferably 20 mg, most preferably between 30 mg to 50 mg of caffeine which is subdivided into a plurality of compacts.
• Each compact contributes a smaller, sub unit dose of said stimulant/ s in association with said immediate and extended energy providers in the form of mono, di and poly saccharides and excipients.
• the sealed pack contains between 5 to 100 said compacts each containing a smaller amount or sub unit dose of caffeine making up a total which is an effective unit dose.
• the invention relates to confunctionery compositions or sweets which may be compacts with at least two visually distinct layers.
• the invention concerns a confectionery composition which conveys a functional benefit.
• a new term 'confunctionery' is used in this specification to describe a category in confectionery that is between a nutriceutical/ pharmaceutical and a confectionery product, combining the functional properties of nutriceuticals with the pleasurable and 'more-ish' qualities of confectionery compositions.
• confunctionery compositions are most edible and suitable for unrestricted sale to the general public in all types of retail outlets.
• the category includes sugar products, chocolates, drinks, beverages, etc.
• a confunctionery product is essentially a confectionery which comprises at least one biologically active compound that has some physiological or pharmacological but above all, functional benefits.
• 'stimulant' is a biologically active compound that stimulates the central nervous system (CNS) in a measurable way including but not limited to maintaining a wakeful and alert state or improving and enhancing cognitive functions
• 'unit dose' is an effective amount of a biologically active compound or therapeutic agent that has a stimulant function. This is an arbitrary or empirical amount generally recognised to be between 30 mg or 50 mg for caffeine base.lt may be less than 30 mg, as little as 10 mg or even less.
• the unit dose for other stimulants varies according to the compound, 'sub unit dose' is a smaller amount of the unit dose in milligrams of a stimulant in each compact.
• pack' is a primary pack or container for the compacts including but not limited to sachets, pouches, wrapped rolls, boxes and the like;
• 'compact' is a consolidated unit or sweet that is held or crunched in the mouth, prepared by shaping a bed of powder or granules in a die by applying pressure through impact or extrusion;
• 'bilayer' describes a compact which is composed of at least two visually distinct layers.
• the invention describes a novel functional confectionery composition for oral administration in the manner of sweets, which may be a solid compact that is held or crunched in the mouth, for extended supply of energy and stimulant(s) from external and endogenous sources, comprising, (a) mixtures of mono, di, and poly saccharides , or combinations with trehalose, (b) at least one active component in a unit dose i.e. an effective amount which is sub divided and distributed into (c) a plurality of solid compacts each comprising a smaller , sub unit dose of said stimulant (d) contained in a unit pack.
• each compact comprises at least two layers which may differ in colour.
• the invention further allows biologically active compounds including but not limited to vitamins, minerals, appetite stimulants or depressants, etc to be included in the composition.
• the total daily amount of e.g. caffeine that may be ingested safely in the manner of sweets is defined by i).the amount of caffeine in each sweet, ii) the number of sweets in a sealed pack. Further, the total caffeine delivered in a pack of sweets may be controlled within safe daily intake levels by selecting suitable values within the two parameters.
• the amount of stimulant e.g. caffeine in each sweet in a sealed pack is most preferably not more than one fifth of the unit dose i.e. effective amount of caffeine contained in the said pack.
• the pack contains between 5 to 100 said compacts.
• an effective dose of caffeine may be between 30 mg to 50 mg. It must be clearly understood that 30 mg -50 mg is an arbitrary range as there is no official recommended dose for caffeine.
• a unit dose of 10 mg or less than 10 mg in total in a pack may be an effective amount if it is administered in an efficient manner.
• the present invention describes an improved delivery system to maximise stimulant effects in combination with energy providing sugars in a compact so that smaller unit doses may be effective. Using the invention it may be possible, where regulation permits, to administer more potent, or bitter and unpalatable compounds, either on their own or preferably combined with caffeine in sub therapeutic amounts in each sweet for frequent or ⁇ rn ingestion.
• the invention overcomes the drawbacks of the known products because there may be fewer undesirable properties normally associated with compositions which deliver a larger amount of a stimulant in one single dose or a shot. Furthermore, subdivision of an effective amount of a stimulant into a plurality of compacts, each comprising a smaller, subunit dose, allows consumption of the active compound more frequently in a palatable form over a longer time. Thus, rather than stressing the organism with a sudden high concentration of the active compound, the level of the active compound may be maintained at an effective level for longer periods. Contrary to known pharmaceutical compositions containing a stimulant in an effective amount e.g. 30 mg to 50 mg in each tablet, the novel 'confunctionery' composition has a pleasant taste and is essentially a sweet and consumed in the manner of sweets to be held in the mouth or crunched with minimal risks from over indulgence.
• the invention comprises a plurality of compacts, at least 5 in a sealed unit pack containing an effective amount of a stimulant composition, wherein each sweet is preferably a bilayered compact formed by compression or moulding, comprising: i) at least one sugar selected from the group consisting of mono, di and poly saccharides as energy provider, ii) a smaller amount of at least one natural or synthetic compound with safe and known CNS stimulant properties, iii) excipients such as artificial sweeteners, flavours and colouring.
• a preferred monosaccharide is e.g. glucose and a particularly preferred disaccharide is trehalose, whilst a preferred polysaccharide is maltodextrin.
• a preferred stimulant is a xanthine such as caffeine or a caffeine salt. Contrary to known caffeine tablets the novel 'confunctionery' composition has the pleasant taste of a sweet and may be consumed in the manner of sweets - as many or as few at a time. Due to the distribution of a unit dose of caffeine into a number of tasteful compacts in a pack wherein each sweet contains a sub tc unit dose or smaller amount of caffeine, the stimulating effect of caffeine may be prolonged by either ingesting one or more sweets in succession or spaced over a period according to requirements.
• caffeine tablets of the prior art leave no choice but to administer a full therapeutic dose of caffeine contained in one or two tablets to be taken with water. This mode of administration stresses the organism with a sudden rather high concentration of caffeine ' which may result in unwanted side effects or rapid clearance. It should be clearly understood that in place of or in addition to caffeine, other stimulant compounds including those with cognitive enhancing properties may be used.
• Preferred embodiments of the compacts have at least two or more layers.
• An embodiment of particular interest is a bilayered tablet comprising two halves with different colours.
• the two halves may contain either the same or different components.
• one half may comprise caffeine or another stimulant whilst the other half may either comprise the same components or different components and flavours.
• the compacts may be round or oval or they may be polygonal. Preferred shapes are three to eight sided polygons, most preferred are six sided hexagonals. The corners of the hexagon allow the sweet to be picked up more easily and prevent rolling.
• the invention includes a unit pack containing a functional confectionery sweet which may comprise a total amount of up to 1000 mg of caffeine, a sealed unit pack which is preferably a resealable gusset type, stand- up pouch fabricated from a 3 ply laminate and heat sealed.
• a functional confectionery sweet which may comprise a total amount of up to 1000 mg of caffeine
• a sealed unit pack which is preferably a resealable gusset type, stand- up pouch fabricated from a 3 ply laminate and heat sealed.
• saccharides in the composition is between about 10 wt% to 90 wt%, used on their own or preferably in combination.
• immediate energy providers are monosaccharides e.g., glucose, fructose, maltose.
• Preferred ranges are between 10 wt% to 40 wt%.
• longer term energy providers are disaccharides such as sucrose, preferably trehalose and polysacharides such as maltodextrins, and/ or smaller amounts of polyols such as xylitol, mannitol, sorbitol, etc and mixtures thereof.
• the wt % of trehalose may be within the range of 1 wt% to 90 wt%, preferably 10 wt % to 90 wt % and most preferably 15 wt% to 75 wt%.
• the ratio of. monosaccharide to disaccharide is preferably 1 : 10 to 10 : 1.
• the stimulant may be a xanthine such as caffeine or its salt including taste masked caffeine, caffeine containing guarana, gingko biloba, phosphatidyl serine (PS), phosphatidyl inositol (PI), glycerophosphocholine and natural products such as gingseng and its alkaloids that are known to have a stimulant effect on the CNS and used in products for general consumption.
• the stimulant may be in a taste masked form that hides the bitter taste.
• stimulants are used which do not have undue legal restrictions on their use.
• Caffeine and its salts, and caffeine containing natural products such as guarana or combinations are particularly preferred as stimulant.
• functional components such as gingseng or a ginsenoside, gingo biloba or a ginkolide may be used as a stimulant with the proviso that an amount recognised as an effective dose is sub-divided and distributed into at least 5 or more sweets in a unit pack, preferably in a resealable gusset pouch as in the case of caffeine illustrated as a typical example.
• Compounds with CNS stimulant properties including cognitive enhancement may be used in much the same way preferably in combination with caffeine. It should be clearly understood that the amount of the stimulant depends on the compound and for highly potent compounds the amount contained in each sweet may be less than 1 microgram.
• Combinations of caffeine and other stimulant compounds are particularly preferred. For example nicotine may be combined with caffeine in a sweet according to the invention.
• the tsub unit dose of caffeine in a single sweet may be between 0.1 mg to 10 mg, more preferably between 0.25 mg to 6 mg, most preferably 2 mg to 5 mg of caffeine alkaloid calculated on the anhydrous base.
• the total amount or unit dose of caffeine contained in each sealed unit pack sold over the counter should not exceed 1000 mg, preferably a total amount of not more than 500 mg, more preferably up to 250 mg, most preferably not exceeding 100 mg total caffeine content.
• the caffeine content may be spread uniformly into up to 1000 individual compacts, preferably between 5 to 100 individual compacts, more preferably between 10 to 50 individual compacts, most preferably between 10 to 30 sweets.
• the caffeine may be combined with other biologically active compounds.
• the caffeine may be in any suitable or taste masked form. In terms of the particle size characteristics of the caffeine, 5% to 30% by weight may be retained on an 80 mesh sieve and at least 50% passes through.
• the invention further describes a method of minimising the risks of acute overdose with a stimulant such as caffeine by providing in a sealed unit pack containing at least 5 sweets and an effective amount of caffeine in a unit dose, preferably a total amount of 10 mg or less to 1000 mg of caffeine, preferably between 20 mg to 500 mg, more preferably or 30 mg to 250 mg most preferably 50 mg to lOOmg, which involves either lowering the amount of caffeine in each compact within the range of 0.1 mg to 10 mg, preferably within the range of 0.25 mg to 6 mg and increasing the number of compacts; or reducing the number of compacts and increasing the. amount of caffeine in each compact within the preferred range. Applying this method, effective dose levels for other stimulants will depend on the compound.
• this invention helps to regulate the amount of caffeine ingested within effective and safe levels in each pack of stimulation sweets.
• the recommended dose and frequency for caffeine tablets such as Pro-Plus ® is 50/100 mg at hourly intervals -with, water.
• Popular drinks provide in excess of 50 mg of caffeine with each consumption whilst coffee can contain more than 500 mg per serving.
• the present invention is more effective in promoting a state of wakefulness. This may be because of, a) the use of smaller or sub-therapeutic amounts of caffeine in subdivided unit doses, b) the sustained and more effective manner in which the caffeine is delivered through oral mucosa when it is held or crunched in the mouth. The absorption of caffeine from oral mucosa is very high.
• oral mucosal absorption avoids first pass metabolism and leads to a much higher bioavailability compared to absorption from the GI tract. Therefore even smaller, sub therapeutic amounts of caffeine may be as effective as giving larger amounts with drinks which are rapidly cleared after ingestion.
• the invention provides a more effective and improved delivery of energy providers and stimulant because of i) the type of energy providers particularly trehalose on its own or in combination with other sugars for immediate and sustained effects, ii) the extended manner in which an effective amount of stimulant is released following oral mucosal and GI absorption from a plurarity of sub therapeutic unit doses, to provide optimal bioavailabilty in terms of AUC, Cmax and Tmax parameters, iii) the application of bilayered compaction technology for slow dissolution and possible taste masking, further facilitating oral mucosal transport, iv) the use of trehalose which has reduced cariogenic properties.
• the invention provides consumer safeguards to limit caffeine overdose whilst maintaining the appeal of sweets by selecting a combination of an amount of caffeine in each sweet and the number of sweets contained in a pack, so that the total amount of caffeine in each pack available to the public is kept well within safe but comestible and effective levels.
• up to 20 packs of sweets each pack containing 25 sweets with 50 mg total caffeine must be consumed to provide about 1000 mg of caffeine - an amount below the maximum daily intake level without serious adverse effects.
• Clearly ingesting this amount of caffeine contained in 500 sweets in a day in this manner is highly unlikely. Therefore the consequence of consuming 500 sweets over a short time is self limiting. More usually, a pack of 25 sweets containing about 50 mg of caffeine in total is likely be consumed over a period, thereby providing a practical and pleasurable method of providing functional benefits throughout the day.
• each compact is between 100 mg to 1000 mg, typically between 250 mg to 750 mg.
• the preferred shape of the compact is a bi-convex hexagon to provide maximum surface area for mucosal contact and absorption.
• Preferably the compacts have at least two bilayers.
• the compacts or sweets may be formed either by direct compression or wet granulation and other methods which are familiar to those skilled in the art.
• Each compact comprises 0.1 mg to 10 mg, preferably between 0.25 mg to 6 mg caffeine and/ or other stimulant/ s in combination with at least one instant energy provider which is a monosaccharide and one intermediate energy provider that is a disaccharide in the ratio of 1:9 to 9:1 by weight.
• the combination of a stimulant in each sweet and the number of sweets constitute an effective therapeutic amount in a sealed pack.
• flavours, colours and excipients including artificial sweeteners may be included.
• Compacts that have a dissolution rate of about 1 minute preferably up to 2 to 5 minutes, are preferred. This is achieved by preparing compacts, preferably with a crushing strength between 100 and 120 Newton using a Schleuniger- 4M hardness tester. Crushing strengths within approximately this range allows either slow dissolution or crunching in the mouth and facilitates oral mucosal delivery. Furthermore, for providing an immediate supply of energy, glucose is preferred. Trehalose, either in crystalline or amorphous forms is used for a somewhat slower release of energy in the GI tract. Although trehalose may be used on its own, combinations of sugars with trehalose are particularly preferred because they may be less cariogenic.
• the invention provides stimulation sweets in a pack for controlled supply of energy sugars and stimulant in tandem by making glucose available immediately, trehalose which is less cariogenic, after breakdown to glucose, in association with caffeine.
• the effects persist beyond the time that each compact dissolves in the mouth, either held or crunched.
• the total amount of energy providers and stimulant delivered by a plurality of compacts consumed over a longer time may be prolonged. It may be up to an hour or more depending on the number of sweets that are ingested.
• This type of continuous delivery and supply of energy providers in association with stimulant may be more effective to. overcome or avoid fatigue and promote wakefulness compared to a similar amount of sugars and caffeine that is taken in one shot in a drink.
• Each unit pack may comprise 5 to 100 individual compacts, preferably 10 to 50 bilayered compacts packed inside a sealed unit pack or container suitable for general retail.
• the pack is a resealable gusset pouch fabricated from a 3 ply laminate material.
• the invention reduces the risks associated with acute overdosing by either lowering the amount of caffeine or a stimulant in each compact and increasing the number of compacts or by reducing the number of compacts and increasing the sub unit dose in each so that the total amount of caffeine or a stimulant in an effective unit dose in a sealed pack amounts to not more than 10 mg (or less) to 1000 mg of ca feine,preferably between 20 mg to 500 mg, more preferably or 30 mg to 250 mg, most preferably 50 mg to 100 mg of caffeine.
• the invention also covers a unit pack wherein the compacts or the like comprise sweet compositions further comprising biologically active materials such as vitamins, functional ingredients, minerals, etc combined with caffeine.
• Trehalose dihydrate 15.0 wt % 10.0 wt % - 75 wt %
• the components are blended using triturates of caffeine and either red or blue colour to obtain homogeneous distribution. Separate amounts of the red and the blue powder mixtures are introduced into the dies of a bilayered Fette tablet machine.
• the weight of each bilayered compact is about 500 mg and typically contains about 2 mg +/- 10% caffeine. 25 sweets are filled into a stand-up gusset type pouch.
• the total amount of caffeine in each pack is about 50 mg delivered with about 11 gm of mono and disaccharides as energy providers.
• the components in the red and blue powder blends may be varied in terms of the active components and/ or the saccharides, or flavours to obtain 2 different compositions in each half.
• Component C Trehalose anhydrous 50.0 wt %
• Component A comprising caffeine is mixed uniformly with half the wt of powders in C and the red colour.
• Component B containing PS is uniformly incorporated as a triturate into C, using the remaining amount of C and the blue colour.
• 250 mg quantities of the red and blue powder compositions comprising caffeine and PS respectively are compressed into bilayered sweets as in Ex 1.
• 500 mg of the bilayered compact comprises a red half with about 2.5 mg caffeine and a blue half with about 6 mg PS.
• 50 bilayered sweets each containing 2.5 mg caffeine and 6 mg PS in separate halves are filled into a resealable gusset pouch as before.
• each half may contain both caffeine and PS.
• Each pack contains a total of 125 mg caffeine and 300 mg PS.
• the minimum effective dose of PS is about 100 mg.
• stimulants may be incorporated in the 2 halves with the same or different saccharide mixtures as in Example 1 or 2 to prepare similar or different combinations of stimulant and sugar.
• caffeine is used either alone or in combination with PS.
• Other types of stimulants may be used in place of caffeine.
• the invention further allows combinations of stimulants with biologically active compounds which are not stimulants. Whilst the broad range of the stimulant should fall within 0.01 wt % to 10 wt % of the composition, the preferred range will depend on the activity of the compound. Preferably this should be in the region of 0.1 wt % to 1 wt % of the weight of each compact.
• each stimulation sweet depends on the total amount of the effective dose that is contained in each sealed pack.
• the preferred example is a bilayered compact where one half of the compact is red and the other half is blue, other colours may be employed.
• Each half of the compact may contain caffeine or stimulant and sugars in similar or different combinations.
• the total weight of the compact is about 500 mg.
• the preferred unit pack is a resealable gusset pouch.
• a preferred pouch material is an aluminium/ plastic composite.
• the size of the pouch measures approximately 50 mm - 80 mm width by 60 mm to 100 mm length.
• the pouch is heat sealed after filling. 10 -20 unit packs are assembled into a secondary pack for point of sale (POS) display and merchandising.
• POS point of sale
• the invention provides a novel functional confectionery or confunctionery composition in a sealed pack, which may be stimulation sweets and in the form of solid compacts, or the like, preferably bilayered, for dissolution in the mouth for extended supply of energy and stimulant from external and endogenous sources, comprising (a) at least one sugar selected from the group consisting of mono, di and polysaccharides or preferably combinations thereof with trehalose, (b) at least one stimulant in an effective amount or unit dose, or in combination with biologically active compound/ s, (c) a plurality of solid compacts, (d) each compact comprising a sub unit dose of the said stimulant. Furthermore, there may be fewer undesirable properties normally associated with stimulation compositions consumed in a single shot in water.

Landscapes

• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Food Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Health & Medical Sciences (AREA)
• Inorganic Chemistry (AREA)
• Nutrition Science (AREA)
• Microbiology (AREA)
• Molecular Biology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Confectionery (AREA)

Priority Applications (1)

Applications Claiming Priority (4)

Publications (1)

Family

ID=32338169

Family Applications (1)

Country Status (3)

Families Citing this family (1)

Family Cites Families (7)

• 2003
  • 2003-11-25 EP EP03767650A patent/EP1565062A1/de not_active Withdrawn
  • 2003-11-25 AU AU2003292110A patent/AU2003292110A1/en not_active Abandoned
  • 2003-11-25 WO PCT/EP2003/013240 patent/WO2004047545A1/en not_active Ceased

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events